EUCTR2017-002345-29-FI
Active, not recruiting
Phase 1
The effect of androgen deprivation therapy on the expression of prostate specific membrane antigen (PSMA) in prostate cancer
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Turku University Hospital
- Enrollment
- 5
- Status
- Active, not recruiting
- Last Updated
- 7 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\-Age: 40 to 85 years old
- •\-Language spoken: Finnish
- •\-Diagnosis: Histologically confirmed adenocarcinoma of prostate
- •\-Adequate histological sampling consisting of at least 3 biopsy samples from each lobe
- •\-No previous surgical, radiation or endocrine treatment for prostate carcinoma
- •\-Clinical stage:
- •\- T1c\-T4N0\-2M0\-1 (Study APhase 1\)
- •\-Serum creatinine \= 1,5 x ULN
- •\-Mental status: Patients must be able to understand the meaning of the study
- •\-Informed consent: The patient must sign the appropriate Ethical Committee (EC) approved informed consent documents in the presence of the designated staff
Exclusion Criteria
- •\-Infections: Patient must not have an uncontrolled serious infection
- •\-Contraindications for MRI (cardiac pacemaker, intracranial clips etc)
- •\-Prior usage of 5\-ARI medication in past 12 months
- •\-Patient preference for active surveillance as a method of prostate cancer management
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
The effect of androgen deprivation therapy on the expression of prostate specific membrane antigeMetastatic prostate cancerMedDRA version: 20.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10071119 Term: Hormone-dependent prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-004853-26-FITurku University Hospital35
Recruiting
Not Applicable
To determine whether androgen deprivation therapy or androgen blockage therapy upregulates receptor activity of Gallium68 Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) scans for men with castrate resistant prostate cancer.ACTRN12617001116314St Vincent's Hospital, Sydney20
Recruiting
Not Applicable
Effect of androgen deprivation therapy on uptake of PSMA ligand in patients with salivary duct carcinoma: an explorative study.NL-OMON48488Radboud Universitair Medisch Centrum14
Not yet recruiting
Phase 3
Effect of systematic lifestyle advice & use of cholesterol reducing drugs on cardiovascular disease outcomes among men with newly diagnosed prostate cancer on androgen deprivation therapy.Health Condition 1: C61- Malignant neoplasm of prostateCTRI/2023/07/054807Dr Jehonathan Pinthus Dr Leong Darryl
Active, not recruiting
Phase 4
The effect of intermittent versus continuous androgen deprivation therapy in Chinese patients with advanced prostate cancer: A prospective controlled Trial from Chinaprostate cancerCancer - ProstateACTRN12613000107729Changhai Hospital, Second Military Medical University100